N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects

References

• Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2):99–106.
   PubMedGoogle Scholar
• Quintavalle C, Donnarumma E, Fiore D, et al. Therapeutic strategies to prevent contrast-induced acute kidney injury. Curr Opin Cardiol. 2013;28:676–682.
   PubMed Web of Science ®Google Scholar
• Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294–321. Epub 2015/05/11.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23:629–636.
   PubMed Web of Science ®Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine–a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7:355–359.
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29:346–351.
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Cornacchia C, Pinnen F, et al. Prodrug approach for increasing cellular glutathione levels. Molecules. 2010;15:1242–1264.
   PubMed Web of Science ®Google Scholar
• Asevedo E, Mendes AC, Berk M, et al. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr. 2014;36:168–175.
   PubMed Web of Science ®Google Scholar
• Chan ED, Riches DW, White CW. Redox paradox: effect of N-acetylcysteine and serum on oxidation reduction-sensitive mitogen-activated protein kinase signaling pathways. Am J Respir Cell Mol Biol. 2001;24:627–632.
   PubMed Web of Science ®Google Scholar
• Domenighetti G, Quattropani C, Schaller MD. [Therapeutic use of N-acetylcysteine in acute lung diseases]. Rev Mal Respir. 1999;16:29–37.
   PubMed Web of Science ®Google Scholar
• Samuni Y, Goldstein S, Dean OM, et al. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830:4117–4129.
   PubMed Web of Science ®Google Scholar
• Shungu DC. N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia. Biol Psychiatry. 2012;71:937–938.
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15:105–110.
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007;164:1115–1117.
   PubMed Web of Science ®Google Scholar
• Amen SL, Piacentine LB, Ahmad ME, et al. Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology. 2011;36:871–878.
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Kalivas PW, Nicholas JS, et al. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013;22:443–452.
   PubMed Web of Science ®Google Scholar
• Mardikian PN, LaRowe SD, Hedden S, et al. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:389–394.
   PubMed Web of Science ®Google Scholar
• Gray KM, Watson NL, Carpenter MJ, et al. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict. 2010;19:187–189.
   PubMed Web of Science ®Google Scholar
• Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169:805–812.
   PubMed Web of Science ®Google Scholar
• Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013;38:1788–1791.
   PubMed Web of Science ®Google Scholar
• Bentzley JP, Tomko RL, Gray KM. Low pretreatment impulsivity and high medication adherence increase the odds of abstinence in a trial of N-Acetylcysteine in adolescents with cannabis use disorder. J Subst Abuse Treat. 2016;63:72–77.
   PubMed Web of Science ®Google Scholar
• McClure EA, Sonne SC, Winhusen T, et al. Achieving cannabis cessation – evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the national institute on drug abuse clinical trials network. Contemp Clin Trials. 2014;39:211–223.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, et al. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res. 2011;17:211–216.
   PubMed Web of Science ®Google Scholar
• Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry. 2009;65:841–845.
   PubMed Web of Science ®Google Scholar
• Prado E, Maes M, Piccoli LG, et al. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep. 2015;20:215–222.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Dodd S, Gama CS, et al. Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. Acta Neuropsychiatr. 2009;21:285–291.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75:39–45.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010;20:823–828.
   PubMed Web of Science ®Google Scholar
• Mousavi SG, Sharbafchi MR, Salehi M, et al. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. Arch Iran Med. 2015;18:28–33.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652–657.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Saldana SN. Treatment with adjunctive N-acetylcysteine in an adolescent with selective serotonin reuptake inhibitor-resistant anxiety. J Child Adolesc Psychopharmacol. 2012;22:472–473.
   PubMed Web of Science ®Google Scholar
• Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:1313–1318.
   PubMed Web of Science ®Google Scholar
• Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71:956–961.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13:196.
   PubMed Web of Science ®Google Scholar
• Nikoo M, Radnia H, Farokhnia M, et al. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38:11–17.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci. 2012;17:985–987.
   PubMed Web of Science ®Google Scholar
• Stutzman D, Dopheide J. Acetylcysteine for treatment of autism spectrum disorder symptoms. Am J Health Syst Pharm. 2015;72:1956–1959.
   PubMed Web of Science ®Google Scholar
• Marler S, Sanders KB, Veenstra-VanderWeele J. N-acetylcysteine as treatment for self-injurious behavior in a child with autism. J Child Adolesc Psychopharmacol. 2014;24:231–234.
   PubMed Web of Science ®Google Scholar
• Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7:26.
   PubMed Web of Science ®Google Scholar
• Dean OM, Gray KM, Villagonzalo KA, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2016 Jun 17. pii: 0004867416652735.
   Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468–475.
   PubMed Web of Science ®Google Scholar
• Dean OM, Bush AI, Copolov DL, et al. Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin Neurosci. 2012;66:514–517.
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, et al. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:132–135.
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr. 2011;33:374–378.
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011;129:317–320.
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, et al. A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry. 2013;47:564–568.
   PubMed Web of Science ®Google Scholar
• Waterdrinker A, Berk M, Venugopal K, et al. Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry. 2015;76:e665–e665.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011;135:389–394.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean OM, Cotton SM, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 2012;10:91.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75:628–636.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Macedo DS, Goulia P, et al. N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression. J Clin Psychopharmacol. 2013;33:719–720.
   PubMed Web of Science ®Google Scholar
• Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology. 2006;184:254–256.
   PubMed Web of Science ®Google Scholar
• Yazici KU, Percinel I. N-acetylcysteine augmentation in children and adolescents diagnosed with treatment-resistant obsessive-compulsive disorder: case series. J Clin Psychopharmacol. 2015;35:486–489.
   PubMed Web of Science ®Google Scholar
• Yazici KU, Percinel I. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation. J Child Adolesc Psychopharmacol. 2014;24:525–527.
   PubMed Web of Science ®Google Scholar
• Van Ameringen M, Patterson B, Simpson W, et al. N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: a case series. J Obsessive Compuls Relat Disord. 2013;2:48–52.
   Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32:797–803.
   PubMed Web of Science ®Google Scholar
• Sarris J, Oliver G, Camfield DA, et al. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29:801–809.
   PubMed Web of Science ®Google Scholar
• Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41:214–219.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Panza KE, Yaffa A, et al. N-acetylcysteine in the treatment of pediatric tourette syndrome: randomized, double-blind, placebo-controlled add-on trial. J Child Adolesc Psychopharmacol. 2016;26:327–334.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Barata AR, Tosti A, Rodriguez-Pichardo A, et al. N-acetylcysteine in the treatment of trichotillomania. Int J Trichology. 2012;4:176–178.
   PubMedGoogle Scholar
• Taylor M, Bhagwandas K. N-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders? Br J Dermatol. 2014;171:1253–1255.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66:756–763.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Panza KE, Grant JE, et al. N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013;52:231–240.
   PubMed Web of Science ®Google Scholar
• Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014;164A:421–424.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. Skin picking disorder. Am J Psychiatry. 2012;169:1143–1149.
   PubMed Web of Science ®Google Scholar
• Silva-Netto R, Jesus G, Nogueira M, et al. N-acetylcysteine in the treatment of skin-picking disorder. Rev Bras Psiquiatr. 2014;36:101.
   PubMed Web of Science ®Google Scholar
• Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol. 2007;27:227–229.
   PubMed Web of Science ®Google Scholar
• Percinel I, Yazici KU. Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine. J Clin Psychopharmacol. 2014;34:772–774.
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Redden SA, et al. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73:490–496.
   PubMed Web of Science ®Google Scholar
• Berk M, Jeavons S, Dean OM, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr. 2009;14:357–360.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem. 2013;12:223–228.
   PubMedGoogle Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–368.
   PubMed Web of Science ®Google Scholar
• Berk M, Munib A, Dean O, et al. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. J Clin Psychiatry. 2011;72:909–913.
   PubMed Web of Science ®Google Scholar
• Dean OM, Mancuso SG, Bush AI, et al. Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Res. 2015;230:982–983.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Berk M, Venugopal K, et al. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:69–75.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Azarkolah A, Adinehfar F, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36:185–192.
   PubMed Web of Science ®Google Scholar
• Bulut M, Savas HA, Altindag A, et al. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry. 2009;10:626–628.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Veltman DJ, Nederveen A, et al. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012;37:2143–2152.
   PubMed Web of Science ®Google Scholar
• Roten A, Baker NL, Gray KM. Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav. 2015;45:119–123.
   PubMed Web of Science ®Google Scholar
• Froeliger B, McConnell PA, Stankeviciute N, et al. The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: a double-blind, placebo-controlled fMRI pilot study. Drug Alcohol Depend. 2015;156:234–242.
   PubMed Web of Science ®Google Scholar
• McClure EA, Baker NL, Gray KM. Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse. 2014;40:285–291.
   PubMed Web of Science ®Google Scholar
• McClure EA, Baker NL, Gipson CD, et al. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse. 2015;41:52–56.
   PubMed Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851–876.
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Getting a knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci. 2011;8:10–14.
   Google Scholar
• Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162–170.
   PubMedGoogle Scholar
• Ghanizadeh A, Akhondzadeh S, Hormozi M, et al. Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem. 2012;19:4000–4005.
   PubMed Web of Science ®Google Scholar
• Leoncini S, De Felice C, Signorini C, et al. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011;16:145–153.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Kauer-Sant’anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111:135–144.
   PubMed Web of Science ®Google Scholar
• Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1677–1681.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. JPN. 2009;34:263–271.
   Google Scholar
• Dean OM, Turner A, Malhi GS, et al. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Rev Bras Psiquiatr. 2015;37:3–12.
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75:218–265.
   PubMed Web of Science ®Google Scholar
• Grados MA, Specht MW, Sung HM, et al. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin Drug Discov. 2013;8:1515–1527.
   PubMed Web of Science ®Google Scholar
• Rothbart R, Amos T, Siegfried N, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2013 Nov 8;(11):CD007662. doi:10.1002/14651858.CD007662.pub2.
   Google Scholar
• Johnson J, El-Alfy AT. Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. Int J Adv Res (Indore). 2016;7:169–184.
   Google Scholar
• Marek GJ, Behl B, Bespalov AY, et al. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol. 2010;77:317–326.
   PubMed Web of Science ®Google Scholar
• Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S10–S4.
   PubMed Web of Science ®Google Scholar
• Pazvantoglu O, Selek S, Okay IT, et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci. 2009;63:693–700.
   PubMed Web of Science ®Google Scholar
• Hummelen R, Hemsworth J, Reid G. Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression. Nutrients. 2010;2:626–651.
   PubMed Web of Science ®Google Scholar
• Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther. 2008;8:1955–1962.
   PubMed Web of Science ®Google Scholar
• Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. JPN. 2011;36:78–86.
   Web of Science ®Google Scholar
• Moussawi K, Pacchioni A, Moran M, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci. 2009;12:182–189.
   PubMed Web of Science ®Google Scholar
• Reichel CM, Moussawi K, Do PH, et al. Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking. J Pharmacol Exp Ther. 2011;337:487–493.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Pagel MA, Hasler BP, et al. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res. 2001;61:7868–7874.
   PubMed Web of Science ®Google Scholar
• Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173–1183.
   PubMed Web of Science ®Google Scholar
• Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593–597.
   PubMed Web of Science ®Google Scholar
• Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. 2001;64:43–51.
   PubMed Web of Science ®Google Scholar
• Altuntas I, Aksoy H, Coskun I, et al. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med. 2000;38:1277–1281.
   PubMed Web of Science ®Google Scholar
• Amrouche-Mekkioui I, Djerdjouri B. N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice. Eur J Pharmacol. 2012;691:209–217.
   PubMed Web of Science ®Google Scholar
• Basha RH, Priscilla DH. An in vivo and in vitro study on the protective effects of N-acetylcysteine on mitochondrial dysfunction in isoproterenol treated myocardial infarcted rats. Exp Toxicol Pathol. 2013;65:7–14.
   PubMed Web of Science ®Google Scholar
• Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. Ann Med. 2008;40:281–295.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016 Feb 23. doi:10.1038/mp.2016.3.
   PubMed Web of Science ®Google Scholar
• Palacio JR, Markert UR, Martinez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res. 2011;60:695–704.
   PubMed Web of Science ®Google Scholar
• Kigerl KA, Ankeny DP, Garg SK, et al. System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp Neurol. 2012;233:333–341.
   PubMed Web of Science ®Google Scholar
• Yang R, Gallo DJ, Baust JJ, et al. Effect of hemorrhagic shock on gut barrier function and expression of stress-related genes in normal and gnotobiotic mice. Am J Physiol Regul Integr Comp Physiol. 2002;283:R1263–R1274.
   PubMed Web of Science ®Google Scholar
• Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Reviews Neurosci. 2009;10:561–572.
   PubMed Web of Science ®Google Scholar
• Reissner KJ, Gipson CD, Tran PK, et al. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addict Biol. 2015;20:316–323.
   PubMed Web of Science ®Google Scholar
• Roberts-Wolfe DJ, Kalivas PW, Glutamate Transporter GLT-1 as a therapeutic target for substance use disorders. CNS Neurol Disord Drug Targets. 2015;14:745–756.
   PubMed Web of Science ®Google Scholar
• Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology. 2008;33:1760–1772.
   PubMed Web of Science ®Google Scholar
• Baker DA, Shen H, Kalivas PW. Cystine/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration. Amino Acids. 2002;23:161–162.
   PubMed Web of Science ®Google Scholar
• Baker DA, Xi ZX, Shen H, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci. 2002;22:9134–9141.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Tsukada H, Nishiyama S, et al. Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine. Ann N Y Acad Sci. 2004;1025:231–235.
   PubMed Web of Science ®Google Scholar
• Lee MY, Chiang CC, Chiu HY, et al. N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies. Neuropharmacology. 2014;81:215–223.
   PubMed Web of Science ®Google Scholar
• Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med. 1998;31:710–715.
   PubMed Web of Science ®Google Scholar
• Palmer LA, Doctor A, Chhabra P, et al. S-nitrosothiols signal hypoxia-mimetic vascular pathology. J Clin Invest. 2007;117:2592–2601.
   PubMed Web of Science ®Google Scholar
• Devi PU, Pillai KK, Vohora D. Facilitation action of N-acetylcysteine on the anticonvulsant effect of sodium valproate in mice. Basic Clin Pharmacol Toxicol. 2006;98:521–522.
   PubMed Web of Science ®Google Scholar
• Bailey B, Blais R, Letarte A. Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death. Ann Emerg Med. 2004;44:401–406.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–134.
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209–221.
   PubMed Web of Science ®Google Scholar
• Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31:217–222.
   PubMed Web of Science ®Google Scholar
• Olsson B, Johansson M, Gabrielsson J, et al. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34:77–82.
   PubMed Web of Science ®Google Scholar
• Heard K, Schaeffer TH. Massive acetylcysteine overdose associated with cerebral edema and seizures. Clin Toxicol (Phila). 2011;49:423–425.
   PubMed Web of Science ®Google Scholar
• Mahmoudi GA, Astaraki P, Mohtashami AZ, et al. N-acetylcysteine overdose after acetaminophen poisoning. Int Med Case Rep J. 2015;8:65–69.
   PubMed Web of Science ®Google Scholar
• Cotgreave IA, Moldeus P. Methodologies for the analysis of reduced and oxidized N-acetylcysteine in biological systems. Biopharm Drug Dispos. 1987;8:365–375.
   PubMed Web of Science ®Google Scholar
• Watson WA, McKinney PE. Activated charcoal and acetylcysteine absorption: issues in interpreting pharmacokinetic data. DICP. 1991;25:1081–1084.
   PubMedGoogle Scholar
• Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4:108–122.
   PubMed Web of Science ®Google Scholar
• Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother. 1988;42:513–519.
   PubMed Web of Science ®Google Scholar